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The development of strictures in Crohn’s disease is a main cause of hospitalization and often represent an indication for
surgery. The diﬀerentiation between inﬂammatory and ﬁbrotic strictures is useful to determine the optimal treatment. Today, the
availability of noninvasive methods to assess the presence and extension of strictures oﬀers new tools for the diagnosis and follow-
up of the disease. Bowel ultrasound, power doppler ultrasound, contrast-enhanced ultrasound, magnetic resonance imaging oﬀer
the additional advantage that they do not expose patients to ionizing radiation. In this paper we provide an update on the accuracy
of these noninvasive methods for the diagnosis of Crohn’s disease.
1.Introduction
The incidence of Crohn’s disease (CD) is increasing world-
wide. The highest incidences have been reported in northern
Europe, the United Kingdom, and North America. In the
past 50 years, the incidence and prevalence in the West has
increased up to 6–15/100,000 and 50–200/100,000 persons,
respectively [1].
CD is a chronic inﬂammatory condition of the gastroin-
testinal tract, in which genetic, psychological, immune, and
inﬂammatory factors have been suggested to play a role in its
pathogenesis [2].
The physiological immune response in the gut to sup-
press a possible over reactivity bowel antigens or antigens
introduced by food. Pizarro et al. [3] suggest that local
TNF production by intestinal epitelial cell may be key in
maintaining proper innate immune defences. Early dete-
rioration of its expression can lead to increased bacterial
penetration and exposure of underlying mucosal immune
cells to commensal antigens, thus triggering the onset of in-
testinal inﬂammation.
T h et r a n s m u r a lﬁ b r o g e n i cp r o c e s so b s e r v e di nC Di s
believed to be induced by a complex interplay between
inﬂammatory and ﬁbrogenic cells. As for other diseases
characterized by ﬁbrosis, myoﬁbroblasts have been suggested
to play a key role in intestinal ﬁbrosis. However, most of the
assumptions on the pathophysiology of ﬁbrosis in CD are
based on data analyzing the ﬁbrogenic process occurring in
other organs.
Strictures are often responsible of patient’s hospitaliza-
tions and surgeries [4]. Histologically, strictures contain
a mixture of inﬂammatory and mesenchymal cells with
deposition of an excess of extracellular matrix, resulting in
diﬀerent degrees of ﬁbrosis [5]. In fact, strictures may be
predominantly inﬂammatory or ﬁbrotic, causing diagnostic
and therapeutic uncertainty. Treatment regimens include
immune modulators, but this therapy fails when there is
intestinal ﬁbrosis [6]. This would require clinical assessment
with noninvasive methods to determine the activity and
extent of disease and to assess intestinal ﬁbrosis.
Bowel ultrasound is useful to detect intestinal and
extraintestinal lesions, including bowel wall thickening,
stenosis with or without bowel dilation, and the presence
of abscesses and ﬁstulae. Contrast-enhanced ultrasound
(CEUS) may show an enhancement of the bowel wall signal
associated with disease activity. In particular, in patients
with stenotic segments and incomplete bowel obstruction,
it is very important to distinguish between ﬁbrosis and2 The Scientiﬁc World Journal
inﬂammation (enhancement with CEUS). These diagnostic
techniques do not expose patients to ionizing radiation haz-
ards and may be repeated frequently during the monitoring
of therapy, particularly to exclude the need for surgery.
Magnetic resonance imaging (MRI) has also been pro-
posed as a useful tool to distinguish between intestinal
inﬂammation and ﬁbrosis. Similarly to bowel ultrasound,
it does not expose to ionizing radiation, but its costs and
accessibility might preclude its frequent use in the mon-
itoring of patients. On the other hand, one of the main
advantages of MRI is that it provides more detailed informa-
tion about disease involvement of the small bowel wall and
possible extraintestinal complications [7].
This paper provides an update of non-invasive diagnosis
of Crohn’s disease, focusing on the role of transabdominal
ultrasound and magnetic resonance in the detection of
intestinalﬁbrosisinCrohn’sdisease.Theaimistodiscussthe
accuracy of abdominal ultrasound and magnetic resonance
in Crohn’s disease in order to establish a proper diagnostic
assessment and optimize treatment.
2. Assessment by Transabdominal Ultrasound
Improvements in technology and increasing experience
with ultrasound in inﬂammatory bowel disease (IBD)
have conﬁrmed the role of ultrasound as a clinical tool
in Gastroenterology Units. Transabdominal ultrasound is
clinically useful as a non-invasive imaging modality in the
diagnosis of IBD by evaluating bowel wall thickness, peri-
intestinal inﬂammatory reaction, and by estimating extralu-
minal complications such as stenosis, ﬁstula, and abscesses.
For these reasons, transabdominal ultrasound has been
proposed as a ﬁrst-line diagnostic tool in assessing patients
with Crohn’s disease regardless of their clinical symptoms
and/or disease activity [7, 8]. In recent studies, sensitivity
of transabdominal ultrasound in detecting Crohn’s disease
ranges from 84 to 93% when compared with endoscopy
and/or radiology as gold standard [9–11]. Speciﬁcity is 98%,
in the study of Astegiano and coworkers [9]p e r f o r m e do n
313 consecutive outpatients presenting with abdominal pain
and irregular bowel habits lasting more than 3 months. It
has been suggested that disease location is the main factor
inﬂuencing the accuracy of ultrasound for the diagnosis of
CD. Sensitivity is lower for less accessible locations such as
rectum (14.2%) and upper small bowel (28.6%) [10].
The initial diagnosis of CD may be supported by ultra-
sound measurement of bowel wall thickness. Most studies
reported normal wall thickness ranging from 1 up to 4mm
[12]. As shown in Figure 1, the ileum wall echotexture (high-
resolution transducers usually permit visualization of ﬁve
layers)andthepossibleinvolvementofcontiguousstructures
could also be informative and should be considered [8].
In particular, a correlation has been found between wall
thickness and disease activity. Wall thickness is signiﬁcantly
higher in active (Crohns Disease Activity Index, CDAI >
150) than in inactive disease (CDAI<150). Moreover an
association between ﬁbrosis and wall thickening was found.
This association is important for diﬀerential diagnosis of
inﬂammatory and ﬁbrotic bowel wall changes. Fibrotic
stenoses are mostly represented in segments with wall thick-
ening <20–30mm, whereas inﬂammatory lesions are more
frequent in segments with >30mm wall thickening [8]. The
addition of an oral nonadsorbable solution (polyethylene
glycol) results in an increase in the sensitivity of ultrasound
in deﬁning anatomic location and extension of segments
with active disease [13, 14].
3. Assessment by Power Doppler and
Contrast-Enhanced Ultrasound
Newer techniques such as power Doppler and the admin-
istration of echo-enhancing agents have further improved
sensitivity and accuracy.
A strong correlation between colour Doppler sono-
graphic vascularity and colonoscopy and histology of the
terminal ileum and the right colon was found [15, 16].
These studies suggest the utility of power Doppler
ultrasound in the assessment of changes of the bowel wall
determined by pharmaceutical treatment.
In patients with CD, the analysis of vascularity after
intravenous injection of Levovist increases the accuracy of
transabdominal ultrasound and may facilitate the diﬀeren-
tiation between inﬂammatory and ﬁbrotic stenosis [17, 18].
Other studies [19, 20] employing second-generation
intravenous contrast agent (SonoVue) reported similar re-
sults in the accuracy of CEUS.
Diﬀerent diﬀusion-perfusion patterns of bowel wall
enhancement can be observed in CD [19, 20], reﬂecting
diﬀerent degrees of disease activity: submucosal prevalent
enhancement, transparietal enhancement starting from the
submucosa, and transparietal enhancement pattern starting
from extravisceral vessels and involving the whole wall
with an external-to-internal direction. These patterns may
represent the basis for a semiquantitative method to assess
wall vascularisation. Serra et al. [19] described a quantitative
method based on the E/W ratio, in which E is the major
thickness of the enhanced layer, and W is the thickness of
the entire wall section.
CEUS is a sensitive tool for the determination of disease
activity and it was seen to be useful in the followup of treat-
ment. In addition, this technique has been helpful in surgical
management, particularly in the decision of conservative
versus surgical treatment [21, 22]. In fact, hypervascularity
of stenosed segments was shown in intestinal obstruction
subsequent to inﬂammatory cause, while hypovascularity
was found in cicatricial stenosis [23].
In a recent study [24] intestinal ﬁbrosis was evaluated
by measuring strain (degree of compression of a material in
response to a force applied to a ﬁxed area), that is developed
in the tissue. In the study, 7 consecutive patients with ste-
nosed segment were studied with ultrasound elasticity imag-
ing. Their stenotic and normal bowel segments were evalu-
ated by ex vivo elastometry and histopathology after surgical
resection. In addition, female Lewis rats undergoing weekly
trinitrobenzene (5 with subsequent acute inﬂammatory
colitis and 6 with chronic intestinal ﬁbrosis) were evaluated.
The study showed that ultrasound elasticity imaging canThe Scientiﬁc World Journal 3
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Figure 1: (a) Thickening of the ileum wall (6.4mm). Maintained laminar aspect of the intestinal wall and (b) enlarged lymph node (white
circle) near the terminal ileum.
diﬀerentiate inﬂammatory from intestinal ﬁbrosis in rat
models, as well as ﬁbrotic lesions from unaﬀected intestine
in patients with CD.
Ultrasound elasticity imaging could identify the patients
with high risk to develop ﬁbrosis and rapidly progress
to ﬁbrostenotic strictures. Therefore, it could be useful in
treatment decision, but future prospective clinical studies are
needed.
4. Assessment by Magnetic Resonance Imaging
MRI provides information about complications and extrain-
testinal manifestations, without exposure to ionizing radia-
tion. The major advantage of MRI over US is the assessment
of the entire gastrointestinal tract [25]. On the contrary, the
disadvantages are the accessibility to this imaging modalities,
greater cost, longer interpretation time and duration of the
exam, contraindication such as claustrophobia, pacemaker,
ferromagnetic vascular clips, ferromagnetic foreign body in
the noble (intracranial, intraocular or vascular), Swan-Ganz
catheter.
MRI is able to provide a rapid and accurate evaluation
of the abdomen and pelvis. In particular, it can be helpful
in providing an evaluation of the activity of perianal CD
[26]. It assesses the features of an altered bowel segment
through characteristic patterns of attenuation and degrees of
enhancement.
Some technical aspects, in particular the distension of
the bowel, enhance the accuracy of MRI. For this reason a
large amount of oral contrast is used in MRI examination.
Oral contrast also decreases the susceptibility to artifacts
by displacing intraluminal air. Positive contrast agents,
represented by paramagnetic substances such as gadolinium
chelates, increase intraluminal signal (hyperintense on both
T1-weighted and T2-weighted). On the contrary, negative
contrast agents reduce intraluminal signal. Moreover, they
improve the visualization of inﬂamed bowel wall and
surrounding fat on T2 images [27]. Bowel wall thickening is
detected on T2 images and bowel wall enhancement is better
appreciated on T1 images. Fat saturation may be used to
increase contrast resolution. This technical aspect also allows
a better assessment of bowel enhancement [28, 29].
Bowel wall thickness can be scored as normal (<3mm),
mildlyabnormal(3–6mm),ormarkedlyabnormal(>6mm)
[30]. The changes characteristically associated with disease
activity are the increase of wall thickness and the enhance-
mentafterinjectionofMRIcontrastandpresenceofoedema.
Borthne et al. [11] compared ultrasound and MRI
using ileocolonoscopy as reference standard in 53 paediatric
patients with suspected IBD. Ultrasound showed higher
sensitivity than MRI (93% versus 82%), but only the
terminal ileum, the location with the highest accuracy for
ultrasound, was examined. In a tertiary care medical center,
120 patients with diagnosis of CD or subjects who were
suspected of having CD underwent MR enterography. MR
enterography demonstrated active CD in 57% of patients,
chronic changes of CD without active inﬂammation (e.g.,
stricture, ﬁstula, or abscess) in 12.5% of cases. The authors
demonstrated that MR Enterography can add signiﬁcant
information to the clinical evaluation of these patients and
wereusefultodetermineifnewsurgicalormedicaltreatment
was required [31]. Figure 2 shows the relapse of disease after
resection and primary anastomosis.
In another tertiary medical center, a study on 213
patientsduring4-yearshowedthat60%ofMREnterography
presented bowel wall thickening and 53% displayed a clear
signal enhancement [32].
Several studies [33–37] have evaluated the accuracy of
MRI in the assessment of activity in the terminal ileum
and/or the colon, showing that a higher accuracy for the
assessment of disease activity can be obtained using luminal
negative contrast.
Del Vescovo et al. [33] studied 16 CD patients who
underwent ileocolonoscopy with biopsy and MRI. The
authors observed a strong correlation between MRI and
histological ﬁndings. Bowel segments with active disease
presented a layered pattern of enhancement, while inactive
disease presented homogeneous contrast uptake. In active
disease, during intravascular phase of contrast distribution,4 The Scientiﬁc World Journal
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Figure 2: (a) MR enterography, T2 weighted sequence (HASTE, half-Fourier axial single-shot fast spin-echo): relapse of segmental disease
associated with segmental wall thickening at the site of previous ileocolic anastomosis; (b) MR enterography T2 weighted sequence
(TrueFISP, true fast imaging with steady-state free precession) delineated proﬁles of segmental wall thickening and mildcomb sign; (c-d) MR
enterography, T1-weighted sequence (VIBE, volumetric interpolated breath-hold examination): postcontrast homogeneous enhancement
of the intestinal wall suggesting a ﬁbrotic lesion.
the authors showed the predominance of vasodilatation
over neoangiogenesis with a fast rise of the mucosa-
submucosa (internal layers) enhancement curve. On the
contrary, muscularis-serosa (external layers) enhancement
curve showed a “slower and lower” trend. In inactive disease,
the predominance of neoangiogenesis over vasodilatation,
probably due to parietal repair of the chronic damage,
resulted in similar trends of the mucosa-submucosa and
muscularis-serosa curves in all phases. The absence of
the enhancement curves between the two layers mucosa-
submucosa and muscularis-serosa in intravascular distri-
bution of contrast agent was likely due to the absence of
vasodilatation.
In Figure 3 the active inﬂammation in CD manifests as
high signal intensity into the bowel wall.
Several studies conﬁrm the possibility to distinguish the
active inﬂammation from the chronic changes of ﬁbrosis
based on diﬀerent enhancement patterns [5, 34, 35].
Figure 4 shows a chronic ﬁbrotic stricture, in which there
is homogeneous contrast enhancement without evidence of
oedema or hyperaemia.
The study of Lasocki and colleagues [34], performed
retrospectively in 26 patients with recent histology (surgery
and/or colonoscopy), showed that MRI is most sensitive
to detect active CD. Moreover, the most sensitive signs
were those related to the bowel wall, namely, thickening,
nodularity, contrast enhancement, and oedema. In the study
of Ha et al. [35] 119 patients with obstructive symptoms
were enrolled. Fifty-ﬁve % of patients required escalation
of medical therapy and 32.5% were directed to surgery. All
MR Enterography studies were performed in fasted patients
followed by oral ingestion of a sorbitol-based biphasic
contrast and it was given immediately prior to scanning the
noncontrast sequences. A single dose of gadolinium contrast
agent was administered before the postcontrast sequences.
The presence of early postcontrast bowel wall enhancementThe Scientiﬁc World Journal 5
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Figure 3: Active inﬂammation in Crohn’s disease: (a) T2W sequence (HASTE): homogeneous wall thickening with intramural focal
hyperintense signal area compliant with active inﬂammation; (b) postcontrast T1W sequence (VIBE) showing mucosal enhancement with
laminar appearance of the wall (with arrows).
(a) (b)
Figure 4: (a) HASTE sequence: mild inﬂammatory activity; distal ileum involved by disease with inhomogeneous wall thickening (white
circle) (b) T1-weighted sequence (VIBE): postcontrast homogenous wall enhancement compliant with ﬁbrotic evolution and reduced
inﬂammatory activity (white arrows).
and thickening in the setting of intermediate to increased
T2 signal intensity bowel wall thickening was classiﬁed as
active inﬂammation. The presence of ﬁbrosis was suggested
by delayed or absent contrast.
InthestudyofLawrenceetal.[36]r espo nset oc o ntin ued
medical therapy after MRI was prospectively assessed at
8-wk. Nonresponders underwent endoscopy. In patients
undergoing surgical resection, the correlation between sur-
gical pathology and the MRI was assessed, conﬁrming the
accuracy of MRI in the classiﬁcation of both inﬂammation
severity and the presence of ﬁbrosis.
Ar e c e n ts t u d y[ 5] was conducted to determine the utility
of magnetization transfer (MT) MRI in the identiﬁcation
and quantiﬁcation of intestinal ﬁbrosis in a rat model of
CD. Magnetization transfer MRI shows diﬀerent molecular
properties with respect to MRI. MT generates contrast that
is primarily determined by the fraction of large macro-
molecules or immobilized phospholipids cell membranes in
tissue. MT is able to determine the ﬁbrotic content of small
bowel strictures. Fibrosis progression was inducted in Lewis
ratsinjectedsubserosallywithpeptidoglycan-polysaccharide.
They develop bowel inﬂammation 1 day after laparotomy
and ﬁbrosis starting 14 days after laparotomy. The authors
performed MRI in 25 rats injected with peptidoglycan-
polysaccharide and 13 injected with human serum albumin
(control animals). They showed that magnetization transfer
can help detect ﬁbrosis and that magnetization transfer ratio
correlates with tissue collagen and it is sensitive to monitor
changesinﬁbrosisprogressionintothenaturalhistoryofCD.6 The Scientiﬁc World Journal
5. Conclusions
Bowel ultrasound should be the ﬁrst-line diagnostic modal-
ity for disease assessment and follow-up examinations with
high accuracy. Ultrasound and MRI can be used in clinical
practice as imaging modalities for assessment of ﬁbrosis in
the terminal ileum and colon. CEUS may be particularly
useful in the followup of patients with CD and for the
assessment of the eﬃcacy of medical therapy in reducing
bowel wall vascularity.
Abbreviations
CD: Crohn’s disease
CEUS: Contrast-enhanced ultrasound
MRI: Magnetic resonance imaging
IBD: Inﬂammatory bowel disease
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